ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
February 21 2024 - 8:32AM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global
bioscience company dedicated to healthy aging, announced that it
will hold a conference call on Wednesday, March 6, 2024 at 4:30
p.m. ET to discuss its financial results for the fourth quarter,
which ended December 31, 2023. The financial results will be
reported in a press release after the close of regular stock market
trading hours on the same day as the conference call.
Investor Conference Call:
ChromaDex management will host an investor conference call to
discuss fourth quarter 2023 results and provide a general business
update on Wednesday, March 6, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the
call. The dial-in information is as follows:
Date: Wednesday, March 6, 2024 Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-596-4144 Conference ID: 8584242
Webcast link: ChromaDex Fourth Quarter 2023 Earnings Conference
Call
The conference call will be broadcast live and available for
replay here and via the investor relations section of the Company’s
website at www.chromadex.com.
A replay of the conference call will be available from 7:30 p.m.
ET on March 6, 2024, to 11:59 p.m. ET on March 13, 2024.
Toll-free replay number: 1-800-770-2030 Replay ID: 8584242
Important Note on Forward Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities and Exchange Act of 1934, as
amended. Statements that are not a description of historical facts
constitute forward-looking statements and may often, but not
always, be identified by the use of such words as “expects,”
“anticipates,” “intends” “estimates,” “plans,” “potential,”
“possible,” “probable,” “believes” “seeks,” “may,” “will,”
“should,” “could,” “predicts,” “projects,” “continue,” “would” or
the negative of such terms or other similar expressions. Risks that
contribute to the uncertain nature of the forward-looking
statements include, but are not limited to, our relationships with
major customers; our ability to maintain our sales, marketing, and
distribution capabilities; a decline in general economic conditions
nationally and internationally; inflationary conditions; the impact
of the COVID-19 pandemic on our business and operations, as well as
the business or operations of our suppliers, customers,
manufacturers, research partners and other third parties with whom
we conduct business; the market and size of the vitamin mineral and
dietary supplement market; decreased demand for our products and
services; market acceptance of our products; the ability to protect
our intellectual property rights; impact of any litigation or
infringement actions brought against us; competition from other
providers and products; risks in product development; our reliance
on of a limited number of third-party party suppliers for certain
raw materials; inability to raise capital to fund continuing
operations; changes in government regulation; the ability to
complete customer transactions and capital raising transactions and
the risks and uncertainties associated with our business and
financial condition in general, described in our filings with the
Securities and Exchange Commission (SEC), including, without
limitation, our most recent Annual Report on Form 10-K and
Quarterly Report on Form 10-Q as filed with the SEC. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, and actual
results may differ materially from those suggested by these
forward-looking statements. All forward-looking statements are
qualified in their entirety by this cautionary statement and
ChromaDex undertakes no obligation to revise or update this release
to reflect events or circumstances after the date hereof.
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240221132898/en/
ChromaDex Media Contact: Kendall Knysch, Director of
Media Relations 310-388-6706 ext. 689 kendall.knysch@chromadex.com
ChromaDex Investor Relations Contact: 949- 356-1620
InvestorRelations@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Apr 2023 to Apr 2024